期刊文献+

氯维地平原料药中有机溶剂残留量测定

Determination of residual organic solvents in raw material clevidipine
下载PDF
导出
摘要 目的:建立氯维地平原料药中有机溶剂残留量测定的方法。方法:采用顶空气相色谱法测定氯维地平原料药中乙醇、丙酮、异丙醇、乙腈、二氯甲烷、异丙醚和乙酸乙酯的残留量。结果:乙醇、丙酮、异丙醇、乙腈、二氯甲烷、异丙醚和乙酸乙酯的定量限分别为15.93、2.01、15.16、5.45、7.85、1.87和0.47μg/ml,检测限分别为3.98、0.50、3.79、2.73、3.93、0.47和0.14μg/ml,线性范围分别为63.71~1 019.4μg/ml(r=0.999 8),64.25~1028μg/ml(r=0.999 9),60.63~970μg/ml(r=0.999 8),5.45~87.2μg/ml(r=0.999 9),7.85~125.6μg/ml(r=0.999 9),59.86~957.8μg/ml(r=0.999 2),61.28~980.4μg/ml(r=0.999 9)。平均加样回收率为96.2%~104.5%,精密度RSD为2.2%~3.7%。结论:该方法准确可靠,重现性好,可用于氯维地平原料药中有机溶剂残留量的控制。 Objective:To establish a method for the determination of residual organic solvents in raw material clevidipine(RMC).Methods:Residual ethanol,acetone,isopropanol,acetonitrile,dichloromethane,isopropyl ether and ethyl acetate ether in RMC were determined by headspace gas chromatography.Results:The quantitative limits were 15.93,2.01,15.16,5.45,7.85,1.87 and 0.47μg/ml,and the detection limits were 3.98,0.50,3.79,2.73,3.93,0.47 and 0.14μg/ml for ethanol,acetone,isopropanol,acetonitrile,dichloromethane,isopropyl ether and ethyl acetate,respectively.Linearity was achieved within the ranges of 63.71-1 019.4μg/ml(r=0.999 8)for ethanol,64.25-1028μg/ml(r=0.999 9)for acetone,60.63-970μg/ml(r=0.999 8)for isopropanol,5.45-87.2μg/ml(r=0.999 9)for acetonitrile,7.85-125.6μg/ml(r=0.999 9)for dichloromethane,59.86-957.8μg/ml(r=0.999 2)for isopropyl ether and 61.28-980.4μg/ml(r=0.999 9)for ethyl acetate,respectively.The average recovery rates were 96.2%-104.5% and the precision RSD was 2.2%-3.7%.Conclusion:The method was accurate,reliable and reproducible,and could be used for the determination of the above residual organic solvents in RMC.
出处 《药学服务与研究》 CAS 2016年第2期118-120,共3页 Pharmaceutical Care and Research
关键词 氯维地平 气相色谱法 顶空 有机溶剂 含量测定 clevidipine gas chromatography headspace organic solvent content determination
  • 相关文献

参考文献2

  • 1Peacock W F, Chandra A, Char D, et al. Clevidipine in acute heart failure: Results of the A Study of Blood Pressure Control in Acute Heart Failure--A Pilot Study (PRONTO)[J ]. Am Heart J,2014,167(4) :529-536.
  • 2黄璐,孙华君,耿海明.氯维地平的研究与临床应用[J].中国新药与临床杂志,2011,30(10):727-731. 被引量:5

二级参考文献22

  • 1ANDERSSON K, NORDLANDER M, WESTERLUND RC. Short- acting dihydropyridines: WO, 95/12578[P]. 1995-05-11.
  • 2NORDLANDER M, SJOQUIST PO, ERICSSON H, et al. Pharmacodynamic, phannacokinetic and clinical effects of clevi- dipine, an ultrashort-acting calcium antagonist for rapid blood pressure control[J]. Cardiovasc Drug Rev, 2004, 22(3): 227- 250.
  • 3ARONSON S, DYKE CM, STIERER KA, et ol. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin,sodiumnitroprusside, and nicardipine for acute hypertension treatment , in cardiac surgery patients[J]. Artesth Analg, 2008, 107 (4): 1110-1121.
  • 4GRADMAN AH, VIVAS Y. New therapeutic perspectives with clevidipine: an ultra-short-acting intravenous Ca2+ channel bloc- ker[J]. Expert Opin Investig Drugs, 2007, 16(9) : 1449-1457.
  • 5VUYLSTEKE A, MILNER Q, ERICSSON H, et al. Pharma- eokinetics and pulmonary extraction of clevidipine, a new vaso-dilating uhrashort-acting dihydropyridine, during cardiopulmo- nary bypass[J]. Br J Anaesth, 2000, 85(5): 683-689.
  • 6ERICSSON H, FAKT C, HOGLUND L, et al. Pharmacokine- tics and phannacodynamics of clevidipine in healthy volunteers after intravenous infusion[J]. Eur J Clin Pharmacol, 1999, 55 (3) : 61-67.
  • 7NGUYEN HM, MA K, PHAM DQ. Clevidipine for the treat- ment of severe hypertension in adults[J]. Clin Ther, 2010, 32 (1): 11-23.
  • 8KIELER-JENSEN N, JOLIN-MELLGAD A, NORDLANDER M, et al. Coronary and systemic hemodynamic effects of clevidipine,an uhra-short-acting calcium antagonist, for treatment of hyper- tension after coronary artery surgery[J]. Acta Anaesthesiol Scand, 2000, 44(2) : 186-193.
  • 9NOVIAWATY I, UZUN G, QURESHI AI. Drug evaluation of clevidipine for acute hypertension[J]. Expert Opin Pharmacother, 2008, 9(14) : 2519-2529.
  • 10ARONSON S. Clevidipine in the treatment of perioperativehypertension: assessing safety events in the ECLIPSE trials[J]. Expet Rev Cardiovasc Ther, 2009, 7(5): 465-472.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部